Navigation Links
Relieving chronic pain
Date:3/25/2013

Each year, more than 35,000 patients in the United States are implanted with spinal cord stimulators to treat chronic pain. Unfortunately, up to half of such patients receive only very limited pain relief. To help more patients, scientists are developing a new device to deliver therapeutic stimulation in a more targeted way, reaching nerve fibers deep within the spinal cord.

Standard devices, first introduced in 1967, work by delivering a low electrical current to the spinal cord that interferes with the body's pain signals. Such devices, however, are only able to deliver therapeutic current to a thin layer of nerve fibers along the outside of the spinal cord. That's because the electrodes delivering the current are placed within the cerebrospinal fluid, which is itself conductive and so dissipates some of the current.

The new device, called the Human Spinal Cord Modulation System (HSCMS), is designed to be in direct contact with the spinal cord, held in place by a small loop of wire. Because the spinal cord moves during normal patient activity, that loop has to exert enough pressure for the HSCMS to stay in contact with the spinal cord but not so much that the pressure restricts blood flow or causes direct injury.

To test the pressure exerted by the HSCMS's design, researchers attached the device to a silicone model of the spinal cord previously developed to have the same biomechanical characteristics as living tissue. They then slowly compressed the loop, measuring the pressure exerted on the silicone model. The results, which were accepted for publication in the American Institute of Physics (AIP) Journal of Applied Physics, show the device's loop design exerts pressure at a similar level as is normally found on the spinal cords of healthy people, and so passes an important safety test for further development of the device.


'/>"/>
Contact: Catherine Meyers
cmeyers@aip.org
301-209-3088
American Institute of Physics
Source:Eurekalert

Page: 1

Related biology news :

1. Relieving plant stress could eventually help humans relax
2. Are survivors of childhood leukemia and lymphoma at greater risk of chronic fatigue as adults?
3. NIH awards nearly $2 million to 3 NYC institutions for chronic fatigue syndrome research
4. Preventing chronic pain with stress management
5. Virology researcher awarded nearly $2 million to study chronic hepatitis E
6. Loneliness, like chronic stress, taxes the immune system
7. Chronic disease research awarded funding
8. Social synchronicity
9. Chronic kidney disease increases risk of death at all ages
10. Viruses not to blame for chronic fatigue syndrome after all
11. B cell survival holds key to chronic graft vs. host disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... WASHINGTON , Dec. 5, 2016  The ... (NIJ), today published "Can CT Scans Enhance or ... examines the potential of supporting or replacing forensic ... a CT scan. In response to ... NIJ is exploring using CT scans as a ...
(Date:12/2/2016)... 1, 2016 The report "Biometric ... Future Technology (Iris Recognition System), Vehicle Type (Passenger ... Forecast to 2021", published by MarketsandMarkets, the market ... 2016, and is projected to grow to USD ... 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:12/2/2016)...   SoftServe , a global digital technology ... electrocardiogram (ECG) biosensor analysis system for continuous driver ... The smart system ensures device-to-device communication between ECG ... mobile devices to easily ,recognize, and monitor users ... technology advances, so too must the security systems ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... 5, 2016 According to ... by Products (Consumable, Instruments, Automated Cell Expansion System), ... Stem Cell Research, Cancer, and Cell-Based Research), End-users ... - Global Revenue, Trends, Growth, Share, Size and ... the global cell expansion market is expected to ...
(Date:12/5/2016)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... Safety Monitoring Board (DSMB) for the Company,s Phase ... patients has completed a second planned safety review ... planned without any modifications. The DSMB reviewed available ... efficacy concerns were identified. The DSMB will conduct ...
(Date:12/5/2016)... , Dec. 5, 2016  Eisai Inc. ... open-label two-year study of rufinamide, which were presented ... Epilepsy Society (AES) held from December 2-6 in ... final two-year safety, tolerability and cognitive data showed ... experienced similar safety and tolerability profiles, cognitive development ...
(Date:12/5/2016)... 2016 The U.S. Biotechnology industry ... billion of revenue and some $890 billion of total ... global biopharmaceuticals, and this figure is expected to exceed ... up these four equities for assessment: Northwest Biotherapeutics Inc. ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
Breaking Biology Technology: